RxDoctor Payments DataLook up a doctor →

Mark Miller, MD

Urology · Cranford, NJNPI 1144219791

Payments from drug & device makers

$24,439in general payments, 2019–2025

Across 461 payments — averaging $53.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$11K
  • Astellas Pharma US Inc$6K
  • Metuchen Pharmaceuticals$3K
  • Myriad Genetic Laboratories, Inc.$678
  • Antares Pharma, Inc.$657
  • Endo Pharmaceuticals Inc.$376
  • plus $3K from 37 others

What the payments were for

  • Speaking & faculty fees$6,63549%
  • Travel & lodging$5574%
  • Food & beverage$6,30246%
  • Education$1761%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,439 in reported general payments places this provider in the 85th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$771,678
Medicare patients
955
Services billed
20,872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron222$221,754
NubeqaDarolutamide16$218,711
ErleadaApalutamide15$218,610
GemtesaVibegron132$151,771
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl213$45,991
OrgovyxRelugolix12$33,478
AvodartDutasteride13$25,483
Tamsulosin Hcl968$19,436
Dutasteride411$13,783
Oxybutynin Chloride ErOxybutynin Chloride333$11,353
Silodosin80$8,002
Alfuzosin Hcl ErAlfuzosin Hcl176$5,655
Testosterone15$4,874
Potassium Citrate ErPotassium Citrate42$4,672
Finasteride267$4,551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$5,702$221,754222 claims
BayerNubeqa$246$218,71116 claims
Johnson & JohnsonErleada$349$218,61015 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$19$185,249144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 401 urology providers in New Jersey.

Other urology in Cranford

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →